PEGIntron plus ribavirin
Phase 3Small molecule
PEGIntron plus ribavirin is one of 26 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
PEGIntron plus ribavirin
HHepatitis Resource Network
Phase 3
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Keyhole-Limpet Hemocyanin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEGIntron plus ribavirin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHepatitis Resource Network